456 related articles for article (PubMed ID: 16968352)
1. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
2. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
3. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
4. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
Kemp R; Miller J; Lungley S; Baker M
N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
[TBL] [Abstract][Full Text] [Related]
5. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
[TBL] [Abstract][Full Text] [Related]
6. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia.
Maher L; Li J; Jalaludin B; Wand H; Jayasuriya R; Dixon D; Kaldor JM
Drug Alcohol Depend; 2007 Jul; 89(2-3):244-50. PubMed ID: 17289299
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience.
Roy E; Boudreau JF; Boivin JF
Drug Alcohol Depend; 2009 Jun; 102(1-3):158-61. PubMed ID: 19251382
[TBL] [Abstract][Full Text] [Related]
8. High hepatitis C incidence in new injecting drug users: a policy failure?
Maher L; Li J; Jalaludin B; Chant KG; Kaldor JM
Aust N Z J Public Health; 2007 Feb; 31(1):30-5. PubMed ID: 17333606
[TBL] [Abstract][Full Text] [Related]
9. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
10. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md.
Nelson KE; Vlahov D; Solomon L; Cohn S; Muñoz A
Arch Intern Med; 1995 Jun; 155(12):1305-11. PubMed ID: 7778962
[TBL] [Abstract][Full Text] [Related]
11. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.
Bruneau J; Roy E; Arruda N; Zang G; Jutras-Aswad D
Addiction; 2012 Jul; 107(7):1318-27. PubMed ID: 22248184
[TBL] [Abstract][Full Text] [Related]
12. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
Smyth BP; Barry J; Keenan E
Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
[TBL] [Abstract][Full Text] [Related]
13. Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users.
Brunton C; Kemp R; Raynel P; Harte D; Baker M
N Z Med J; 2000 Mar; 113(1106):98-101. PubMed ID: 10836310
[TBL] [Abstract][Full Text] [Related]
14. Young and recent-onset injecting drug users are at higher risk for HIV.
Fennema JS; Van Ameijden EJ; Van Den Hoek A; Coutinho RA
Addiction; 1997 Nov; 92(11):1457-65. PubMed ID: 9519489
[TBL] [Abstract][Full Text] [Related]
15. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
[TBL] [Abstract][Full Text] [Related]
16. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
17. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
18. [Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW
Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801
[TBL] [Abstract][Full Text] [Related]
19. Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users.
Day C; Conroy E; Lowe J; Page J; Dolan K
Aust J Rural Health; 2006 Jun; 14(3):120-5. PubMed ID: 16706881
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.
Spittal PM; Craib KJ; Wood E; Laliberté N; Li K; Tyndall MW; O'Shaughnessy MV; Schechter MT
CMAJ; 2002 Apr; 166(7):894-9. PubMed ID: 11949985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
